Mirus Advises American Biological Technologies on Sale to Fujirebio Diagnostics

Mirus Capital Advisors, a veteran middle-market investment bank, announced that it has advised American Biological Technologies (ABT) on the sale of its business to Fujirebio Diagnostics, a world leader in cancer diagnostics and biomarker assays. ABT is a leading contract manufacturer of in vitro diagnostic assay controls and calibrators with operations in Seguin, TX.

“The investment banking team at Mirus Capital Advisors exceeded my expectations for professionalism and service”, said Mike Schrage, who has owned ABT for twenty years. “Their thoughtful and timely advice was instrumental in helping our management team to navigate the sale process without letting it become too much of a distraction”.

The transaction marks Fujirebio Diagnostics’ entry into the controls and calibrators manufacturing business, and the merger will enable the company to further strengthen its position in the evolving in vitro diagnostics industry.

“For more than 20 years, Fujirebio Diagnostics has been on the forefront of oncology diagnostics, bringing to market vital biomarker assays that enable clinicians to better manage cancer,” said Paul Touhey, president and CEO of Fujirebio Diagnostics. “This acquisition is a natural next step on our path to entering diagnostic assay control and calibrator manufacturing, and mirrors Fujirebio Diagnostics’ strategy to provide its diagnostic industry customers with the tools and services that will revolutionize how disease is diagnosed and managed”.

About Mirus Capital Advisors:

Mirus Capital Advisors provides investment banking solutions to corporate clients in technology, business services, manufacturing, consumer products, health care and the resort & hospitality industry. Since 1987, Mirus has provided corporate finance advisory services on engagements including mergers, acquisitions, divestitures, recapitalizations and valuations. For additional information, visit www.merger.com.

About American Biological Technologies:

The products developed by American Biological Technologies are designed to work with a wide variety of diagnostic equipment and in virtually any diagnostic laboratory. The Company provides turnkey manufacturing, filling and packaging services to its customers.

About Fujirebio Diagnostics:

Fujirebio Diagnostics is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. Fujirebio Diagnostics is a wholly owned subsidiary of Fujirebio Inc. Fujirebio Inc. is a leading healthcare company in Japan with a focus on diagnostics, and is a group company of Miraca Holdings. Fujirebio Diagnostics has a worldwide distribution network which enables physicians and patients to access its diagnostic products. For more information about Fujirebio Diagnostics visit www.fdi.com.